TY - JOUR
T1 - Consensus statement on microglial and macrophage functions in gliomas
AU - Zheng, Yuqi
AU - Alzoubi, Islam
AU - Graeber, Manuel B
AU - Anand, Atul
AU - Barazzuol, Lara
AU - Dorostkar, Mario
AU - Frontzek, Karl
AU - Golebiewska, Anna
AU - Hadjipanayis, Costas G
AU - Hortobagyi, Tibor
AU - Ismail, Azzam
AU - Jansen, Gerard H
AU - Kaminska, Bozena
AU - Kirschenbaum, Daniel
AU - Komohara, Yoshihiro
AU - Kristensen, Bjarne Winther
AU - Lee, Kevin S
AU - Le Rhun, Emilie
AU - Lu, Q Richard
AU - Matiasek, Kaspar
AU - Mawrin, Christian
AU - Michelucci, Alessandro
AU - Montemurro, Nicola
AU - Mouthon, Marc-André
AU - Liu, Quan
AU - Reimann, Regina
AU - Sankowski, Roman
AU - Schcolnik-Cabrera, Alejandro
AU - Schulz, Michael
AU - Schürch, Christian M
AU - Schwabenland, Marius
AU - Tchoghandjian, Aurélie
AU - Valiulytė-Simaitė, Indrė
AU - Viapiano, Mariano S
AU - Weiss, Tobias
AU - Weller, Michael
AU - Wintermark, Max
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/6
Y1 - 2026/6
N2 - This international consensus statement synthesizes key findings on the complex roles of microglia and macrophages (tumor-associated microglia/macrophages or TAMs) in glioma progression and therapeutic resistance. Recent advances have highlighted the cellular, spatial, and temporal heterogeneity of TAMs, their functional plasticity, and the intricate interactions between TAMs, glioma stem cells, and the neuronal microenvironment, challenging the M1/M2 classification paradigm for TAMs in gliomas and other misconceptions. The statement emphasizes that glioma cells manipulate TAMs to suppress anti-tumor functions, while microglia-mediated modulation of neuron-glioma cell interactions promotes tumor progression. Furthermore, glioblastoma-derived extracellular vesicles (EVs) reprogram microglia to support tumor progression, offering novel therapeutic targets. To advance research and develop more effective treatments, the statement advocates for precision therapies targeting specific TAM subsets or functions, the use of bioengineered EVs as a therapeutic approach, and a shift away from simplistic terminology like "M1/M2" and "neuroinflammation". Ultimately, this new understanding can support innovative strategies to modulate the tumor microenvironment, turning immunosuppression into immunostimulation and improving outcomes for patients with glioblastoma and other types of gliomas.
AB - This international consensus statement synthesizes key findings on the complex roles of microglia and macrophages (tumor-associated microglia/macrophages or TAMs) in glioma progression and therapeutic resistance. Recent advances have highlighted the cellular, spatial, and temporal heterogeneity of TAMs, their functional plasticity, and the intricate interactions between TAMs, glioma stem cells, and the neuronal microenvironment, challenging the M1/M2 classification paradigm for TAMs in gliomas and other misconceptions. The statement emphasizes that glioma cells manipulate TAMs to suppress anti-tumor functions, while microglia-mediated modulation of neuron-glioma cell interactions promotes tumor progression. Furthermore, glioblastoma-derived extracellular vesicles (EVs) reprogram microglia to support tumor progression, offering novel therapeutic targets. To advance research and develop more effective treatments, the statement advocates for precision therapies targeting specific TAM subsets or functions, the use of bioengineered EVs as a therapeutic approach, and a shift away from simplistic terminology like "M1/M2" and "neuroinflammation". Ultimately, this new understanding can support innovative strategies to modulate the tumor microenvironment, turning immunosuppression into immunostimulation and improving outcomes for patients with glioblastoma and other types of gliomas.
KW - Humans
KW - Microglia/pathology
KW - Glioma/pathology
KW - Macrophages/immunology
KW - Brain Neoplasms/immunology
KW - Tumor Microenvironment/physiology
KW - Consensus
KW - Animals
UR - https://www.scopus.com/pages/publications/105035815959
U2 - 10.1007/s00401-026-02999-3
DO - 10.1007/s00401-026-02999-3
M3 - Review article
C2 - 41991797
SN - 0001-6322
VL - 151
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 1
M1 - 39
ER -